Moran Wealth Management LLC Purchases 55,756 Shares of DaVita Inc. (NYSE:DVA)

Moran Wealth Management LLC raised its holdings in shares of DaVita Inc. (NYSE:DVA) by 102.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 110,322 shares of the company’s stock after acquiring an additional 55,756 shares during the quarter. Moran Wealth Management LLC’s holdings in DaVita were worth $16,499,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Janney Montgomery Scott LLC boosted its holdings in DaVita by 16.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 24,591 shares of the company’s stock worth $4,031,000 after buying an additional 3,468 shares during the period. Asset Management One Co. Ltd. boosted its holdings in shares of DaVita by 4.7% in the third quarter. Asset Management One Co. Ltd. now owns 19,629 shares of the company’s stock worth $3,218,000 after acquiring an additional 886 shares during the period. QRG Capital Management Inc. grew its position in shares of DaVita by 5.0% in the third quarter. QRG Capital Management Inc. now owns 4,577 shares of the company’s stock valued at $750,000 after purchasing an additional 216 shares in the last quarter. CWA Asset Management Group LLC bought a new stake in shares of DaVita during the 3rd quarter valued at $444,000. Finally, Atria Investments Inc lifted its holdings in DaVita by 12.3% during the 3rd quarter. Atria Investments Inc now owns 2,897 shares of the company’s stock worth $475,000 after purchasing an additional 317 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Finally, Barclays increased their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, DaVita has a consensus rating of “Hold” and an average price target of $166.33.

DaVita Trading Up 4.5 %

Shares of DVA opened at $146.73 on Monday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The company has a market capitalization of $11.74 billion, a P/E ratio of 13.66, a P/E/G ratio of 1.07 and a beta of 0.99. The firm’s 50 day simple moving average is $159.43 and its 200 day simple moving average is $157.95.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.